Morgan Stanley analyst Maxwell Skor assumes coverage on CRISPR Therapeutics (NASDAQ: CRSP) with a Equalweight rating and a price target ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments New Coverage